Package Leaflet: Information for the User
Zonisamida Sandoz 25 mg Hard Capsules EFG
Zonisamida Sandoz 50 mg Hard Capsules EFG
Zonisamida Sandoz 100 mg Hard Capsules EFG
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
-This medicine has been prescribed for you only. Do not pass it on to others even if their symptoms are the same as yours. It may harm them.
1.What Zonisamida Sandoz is and what it is used for
2.What you need to know before you start taking Zonisamida Sandoz
3.How to take Zonisamida Sandoz
4.Possible side effects
5Storage of Zonisamida Sandoz
6.Contents of the pack and additional information
Zonisamida Sandoz contains the active ingredient zonisamida, and is used as an antiepileptic.
Zonisamida is used to treat seizures that affect a part of the brain (partial seizures), which may or may not be followed by a seizure that affects the whole brain (secondary generalization).
Zonisamida may be used:
Do not take Zonisamida Sandoz:
Warnings and precautions
Zonisamida belongs to a group of medications (sulfonamides) that may cause severe allergic reactions, severe rashes, and blood disorders, which very rarely may cause death (see section 4. Possible side effects).
There have been cases of severe rashes associated with zonisamida treatment, including cases of Stevens-Johnson syndrome. |
The use of zonisamida may cause high levels of ammonia in the blood, which could change brain function, especially if you are also taking other medications that can increase ammonia levels (e.g., valproate), if you have a genetic disorder that causes excessive ammonia production in the body (urea cycle disorder), or if you have liver disorders. Inform your doctor immediately if you feel drowsy or confused in an unusual way.
Consult your doctor or pharmacist before starting to take zonisamida if:
Inform your doctor, as you may need to be monitored.
Inform your doctor if any of these statements apply to you before taking zonisamida.
Children and adolescents
Consult your doctor about the following risks:
Prevention of heatstroke and dehydration in children Zonisamida may cause your child to sweat less or experience heatstroke; this can cause brain damage and death if not treated. Children are the most vulnerable group, especially on hot days. While your child is taking zonisamida:
carbonic anhydrase inhibitors (such as topiramate and acetazolamide) and anticholinergics (such as clomipramine, hydroxyzine, diphenhydramine, haloperidol, imipramine, and oxybutynin). If your child's skin is very hot with little or no sweating, the child feels confused or has muscle cramps, or their heart rate or breathing is rapid.
|
Do not administer this medication to children under 6 years old, as the potential benefits may not outweigh the risks in this age group.
Taking Zonisamida Sandoz with other medications
Inform your doctor or pharmacist if you aretaking, havetakenrecentlyor may need to take any other medication.
Taking Zonisamida Sandoz with food and drinks
Zonisamida can be taken with or without food.
Pregnancy, breastfeeding, and fertility
Women of childbearing age must use effective contraceptive measures during zonisamida treatment and for one month after stopping zonisamida.
If you plan to become pregnant, talk to your doctor before stopping contraceptives and before becoming pregnant about the possibility of switching to other suitable treatments. If you are or think you may be pregnant, inform your doctor immediately.Do not stop taking this medication without consulting your doctor.
Only take zonisamida during pregnancy if your doctor indicates it. Research shows a higher risk of birth defects in children of women taking antiepileptic medications. The risk of birth defects or neurological developmental disorders (brain development problems) for your child after taking zonisamida during pregnancy is unknown. A study showed that babies born to mothers taking zonisamida during pregnancy were smaller than expected for their age at birth, compared to babies born to mothers treated with lamotrigine monotherapy. Make sure you are fully informed about the risks and benefits of using zonisamida for epilepsy during pregnancy.
Do not breastfeed while taking zonisamida or for one month after stopping zonisamida.
There are no clinical data on the effects of zonisamida on human fertility. Animal studies have shown changes in fertility parameters.
Driving and operating machinery
Zonisamida may affect concentration, reaction time, and may cause drowsiness, especially at the beginning of treatment or after increasing the dose. If zonisamida affects you in this way, be extra careful when driving or operating machinery.
Zonisamida Sandoz contains sodium
This medication contains less than 23 mg of sodium (1mmol) per capsule; this is essentially "sodium-free".
Follow exactly the administration instructions of this medication as indicated by your doctor.This medicationindicated by your doctor.In case of doubt, consult your doctor or pharmacist again.
The recommended dose in adultsis:
If you take zonisamide alone:
If you take zonisamide with other antiepileptic medications:
Use in children (6 to 11 years old) and adolescents (12 to 17 years old) who weigh at least 20 kg:
Example: a child weighing 25 kg should take 25 mg once a day during the first week, and then the daily dose should be increased by 25 mg at the beginning of each week until the daily dose of 150 to 200 mg is reached.
If you estimate that the action of zonisamide is too strong or too weak, inform your doctor or pharmacist.
If you take more Zonisamide Sandoz than you should
If you have taken more zonisamide than you should, inform immediately the person who takes care of you (family member or friend), your doctor or pharmacist, or contact the nearest hospital emergency service and bring the medication with you. You may feel drowsy and may lose consciousness. You may also feel like vomiting, have stomach pain, muscle spasms, eye movement, feel like fainting, have a slow heart rate and decreased respiratory rate and renal function. Do not attempt to drive.
If you have taken more zonisamide than you should, consult your doctor, your pharmacist or call the Toxicological Information Service, phone: 91 562 04 20, indicating the medication and the amount used.
If you forgot to take Zonisamide Sandoz
If you interrupt the treatment with Zonisamide Sandoz
If you have any other questions about the use of thismedication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
Zonisamide belongs to a group of medicines (sulfonamides) that may cause severe allergic reactions, severe rashes, and blood disorders, which very rarely may cause death.
Immediately contact your doctor if:
Contact your doctor as soon as possible if:
Your doctor may decide that you should stop taking zonisamide.
The most frequently reported side effects of zonisamide are mild in nature. They occur during the first month of treatment and often decrease as treatment continues. In children aged 6 to 17 years, the side effects were consistent with the following, except for the following exceptions: pneumonia, dehydration, decreased sweating (frequent), and abnormal liver enzymes (infrequent).
Very common side effects: may affect more than 1 in 10 people
Common side effects: may affect up to 1 in 10 people
Rare side effects: may affect up to 1 in 100 people
Very rare side effects: may affect up to 1 in 10,000 people
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through theSistema Español de Farmacovigilancia de medicamentos de Uso Humano:https://www.notificaram.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keepthis medicationout of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears onthe blister pack and packagingafter CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Do not use this medication if you observe any sign of deterioration in the capsules, blister pack or packaging, or any visible sign of deterioration in the medication. Return the packaging to your pharmacist.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Zonisamida Sandoz
Zonisamida Sandoz 25 mg hard capsules
Capule content: microcrystalline cellulose, hydrogenated vegetable oil and sodium lauryl sulfate.
Capule coating: gelatin, titanium dioxide (E171).
Printing ink: shellac, iron oxide black (E172) and potassium hydroxide.
Zonisamida Sandoz 50 mg hard capsules
Capule content: microcrystalline cellulose, hydrogenated vegetable oil and sodium lauryl sulfate.
Capule coating: gelatin, titanium dioxide (E171).
Printing ink: shellac and iron oxide red (E172).
Zonisamida Sandoz 100 mg hard capsules
Capule content: microcrystalline cellulose, hydrogenated vegetable oil and sodium lauryl sulfate.
Capule coating: gelatin, titanium dioxide (E171).
Printing ink: shellac, iron oxide black (E172) and potassium hydroxide.
Appearance of the product and contents of the package
Zonisamida 25 mg hard capsules have a white opaque body with a white opaque cap, size No. 4, 14.4 mm, marked with “Z 25” in black.
Zonisamida 50 mg hard capsules have a white opaque body with a white opaque cap, size No. 3, 15.8 mm, marked with “Z 50” in red.
Zonisamida 100 mg hard capsules have a white opaque body with a white opaque cap, size No. 1, 19.3 mm, marked with “Z 100” in black.
Zonisamida Sandoz capsules are packaged in blisters that are in turn packaged in boxes containing:
-25 mg: 14, 28 and 56 capsules.
-50 mg: 14, 28 and 56 capsules.
-100 mg: 28, 56, 98 and 196 capsules.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Manufacturer responsible
Noucor Health, S.A.
Avda. Camí Reial, 51-57
08184 Palau-solità i Plegamans (Barcelona)
Spain
or
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1, Sachsen-Anhalt
39179 Barleben
Germany
or
Lek d. d.
Verovskova ulica 57
1526 Ljubljana
Slovenia
This medicine is authorized in the member states of the European Economic Area with the following names:
MaltaZonisamide – 1 A Pharma 25 mg / 50 mg / 100 mg hard capsules
Bulgaria???????????????25 mg / 50 mg / 100 mg?????????????
Czech RepublicZonisamid Sandoz 25 mg / 50 mg / 100 mg tvrdé tobolky
CyprusZonisamide Sandoz 25mg / 50 mg / 100 mg
GermanyZonisamid – 1 A Pharma 25 mg / 50 mg / 100 mg Hartkapseln
DenmarkZonisamide 1A Farma
EstoniaZonisamide Sandoz
SpainZonisamida Sandoz 25 mg / 50 mg / 100 mg cápsulas duras EFG
FranceZonisamide Sandoz 25 mg / 50 mg / 100 mg gélule
CroatiaZonisamid Sandoz 25 mg / 50 mg / 100 mg tvrde kapsule
ItalyZonisamide Sandoz
LithuaniaZonisamide Sandoz 25 mg / 50 mg / 100 mg kietosios kapsules
LatviaZonisamide Sandoz 25 mg / 50 mg / 100 mg cietas kapsulas
NetherlandsZonisamide Sandoz 25 mg /50 mg / 100 mg, harde capsules
PolandZonisamide Sandoz
SwedenZonisamide1A Farma
SloveniaZonisamid Sandoz 25 mg / 50 mg / 100 mg trde capsule
SlovakiaZonisamid Sandoz 25 mg / 50 mg / 100 mg
Last review date of thisleaflet:May 2023
The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.